Lenalidomide—A Transforming Therapeutic Agent in Myelodysplastic Syndromes-Reference-Cited by-同舟云学术

Lenalidomide—A Transforming Therapeutic Agent in Myelodysplastic Syndromes

Published:2009-09 Issue: Volume:9 Page:S302-S304
ISSN:1557-9190
Container-title:Clinical Lymphoma and Myeloma
language:en
Short-container-title:Clinical Lymphoma and Myeloma

Author:

List Alan

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology,General Medicine

Reference16 articles.

1. Immunomodulatory drugs (IMiDs): a new treatment option for myelodysplastic syndromes;Kale;Curr Pharm Biotechnol,2006

2. Amino-substituted thalidomide analogs: Potent inhibitors of TNF-alpha production;Muller;Bioorg Med Chem Lett,1999

3. The evolution of thalidomide and its IMiD derivatives as anticancer agents;Bartlett;Nat Rev Cancer,2004

4. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha;Corral;J Immunol,1999

5. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells;Verhelle;Cancer Res,2007

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML;Blood Reviews;2022-11

2. Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5q;Cancers;2021-10-11

3. Non-chemotherapy Options for Newly Diagnosed Mantle Cell Lymphoma;Current Treatment Options in Oncology;2021-09-15

4. SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q;Clinical Lymphoma Myeloma and Leukemia;2018-10

5. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond;Seminars in Hematology;2017-07